Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidaza in Chronic Myelomonocytic Leukemia
NCT01350947Phase 2Completed
- Sponsor
- University of Utah
- Start
- Apr 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by University of Utah. Primary endpoint: Complete Hematologic Response at 24 months. Started Apr 2011; status: completed.
02
Drugs
azacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01350947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350947.